Volume 29, Number 1—January 2023
Dispatch
Using Serum Specimens for Real-Time PCR-Based Diagnosis of Human Granulocytic Anaplasmosis, Canada
Table 1
Sample no. | IFA titer | Serum Ct values |
Whole blood Ct values |
∆Ct | Td‡ | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Ct-I | Ct-R | Average† | Result | Ct-I | Ct-R | Average† | Result | |||||
1 | <1:64 | 19.9 | NS | 19.9 | Positive | 17.7 | 16.1 | 16.9 | Positive | 3 | 5 | |
2 | <1:64 | 21.8 | NS | 21.8 | Positive | 22 | 21.1 | 21.55 | Positive | 0.25 | 3 | |
3 | <1:64 | 22.8 | 21.8 | 22.3 | Positive | 22.1 | 21.5 | 21.8 | Positive | 0.5 | 0 | |
4 | <1:64 | 22.9 | NS | 22.9 | Positive | 18.5 | 17.9 | 18.2 | Positive | 4.7 | 0 | |
5 | <1:64 | 23 | 22.5 | 22.75 | Positive | 20.5 | 19.7 | 20.1 | Positive | 2.65 | 1 | |
6 | <1:64 | 23.3 | 22.1 | 22.7 | Positive | 19.1 | 18.1 | 18.6 | Positive | 4.1 | 1 | |
7 | <1:64 | 24.2 | 24.2 | 24.2 | Positive | 21.2 | 20.9 | 21.05 | Positive | 3.15 | 1 | |
8 | 1:2048 | 25 | 25.8 | 25.4 | Positive | 22 | 21.9 | 21.95 | Positive | 3.45 | 0 | |
9 | <1:64 | 26.6 | 26 | 26.3 | Positive | 24.6 | 25.4 | 25 | Positive | 1.3 | 0 | |
10 | <1:64 | 26.6 | 25.6 | 26.1 | Positive | 23.2 | 23.5 | 23.35 | Positive | 2.75 | 0 | |
11 | 1:512 | 27 | NS | 27 | Positive | 24.8 | 25.3 | 25.05 | Positive | 1.95 | 2 | |
12 | 1:64 | 28 | 25.3 | 26.65 | Positive | 28.6 | 29.2 | 28.9 | Positive | −2.25 | 0 | |
13 | <1:64 | 28.6 | 27.5 | 28.05 | Positive | 23 | 22.6 | 22.8 | Positive | 5.25 | 0 | |
14 | <1:64 | 28.8 | 28.1 | 28.45 | Positive | 33 | 33.3 | 33.15 | Positive | −4.7 | 3 | |
15 | <1:64 | 29.2 | 28.3 | 28.75 | Positive | 27.7 | 27.1 | 27.4 | Positive | 1.35 | 0 | |
16 | 1:2048 | 29.9 | 27.4 | 28.65 | Positive | 26.9 | 27 | 26.95 | Positive | 1.7 | 0 | |
17 | 1:64 | 30 | 29.2 | 29.6 | Positive | 22 | 21.8 | 21.9 | Positive | 7.7 | 0 | |
18 | <1:64 | 31.7 | 31.7 | 31.7 | Positive | 30.5 | 30.2 | 30.35 | Positive | 1.35 | 0 | |
19 | <1:64 | 32.4 | 33.5 | 32.95 | Positive | 26.4 | 26.2 | 26.3 | Positive | 6.65 | 0 | |
20 | 1:512 | 32.8 | 31.7 | 32.25 | Positive | 37 | 36.5 | 36.75 | Positive | −4.5 | 8 | |
21 | <1:64 | 36.4 | 37.8 | 37.1 | Positive | 37.8 | 37.8 | 37.8 | Positive | −0.7 | 0 | |
22 | <1:64 | 36.5 | 35.8 | 36.15 | Positive | 28.4 | 28.5 | 28.45 | Positive | 7.7 | 0 | |
23 | <1:64 | 36.7 | 36 | 36.35 | Positive | 32.5 | 32.7 | 32.6 | Positive | 3.75 | 0 | |
24 | <1:64 | 37.7 | 36.3 | 37 | Positive | 34 | 34 | 34 | Positive | 3 | 0 | |
25 | 1:1024 | 37.8 | 37.4 | 37.6 | Positive | 32 | 32 | 32 | Positive | 5.6 | 0 | |
26 | 1:256 | 38.2 | 38.3 | 38.25 | Positive | 25.1 | 24.8 | 24.95 | Positive | 13.3 | −84 | |
27 | <1:64 | 38.3 | 40 | 39.15 | Negative | 37.2 | 37.6 | 37.4 | Positive | 1.75 | 0 | |
28 | <1:64 | 38.4 | 35.3 | 36.85 | Positive | 24.1 | 24.2 | 24.15 | Positive | 12.7 | −4 | |
29 | <1:64 | 38.8 | 38.2 | 38.5 | Positive | 31.3 | 31.2 | 31.25 | Positive | 7.25 | 0 | |
30 | <1:64 | 40 | 38.3 | 39.15 | Negative | 38.9 | 39.5 | 39.2 | Positive | −0.05 | 0 | |
31 | <1:64 | 40 | 40 | 40 | Negative | 35.3 | 36.7 | 36 | Positive | 4 | 0 | |
32 | 1:64 | 40 | 40 | 40 | Negative | 33.4 | 32.9 | 33.15 | Positive | 6.85 | 0 | |
33 | <1:64 | 40 | 40 | 40 | Negative | 30.9 | 31.0 | 30.95 | Positive | 9.05 | 0 |
*Only Ct values <40 after repeat extraction were deemed positive. Ct, cycle threshold; Ct-I, Ct values for initial extraction; Ct-R, confirmatory Ct values for repeat extraction; ∆Ct, difference between average serum Ct and average whole blood Ct; IFA, indirect immunofluorescence assay; NS, no sample remaining for repeat extraction; Td, time difference in days between serum sampling (earlier) and whole blood sampling (later). †Average of Ct-I and Ct-R for each isolate. ‡Negative numbers indicate that whole blood was sampled before serum samples.
Page created: November 16, 2022
Page updated: December 22, 2022
Page reviewed: December 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.